Active Trials

Total Trials

Organizations

Events

Finland

Medical Only (Private)

Reimbursed Care Access

Finland maintains a restrictive controlled‑substance regime: pharmaceutical esketamine (Spravato) is an authorised medicine in the EU and available in Finland under prescription and supervised administration, while generic ketamine is an established medical anaesthetic (and occasionally used off‑label in psychiatric emergency settings) but psychedelic classical compounds (psilocybin, MDMA, DMT, 5‑MeO‑DMT, ibogaine, ayahuasca/DMT plant preparations, mescaline, and 2C‑X) are scheduled as narcotics with no routine medical reimbursement except in authorised clinical research. Reimbursement of any medicine in Finland is governed by decisions of the Pharmaceuticals Pricing Board (Hila) and Kela; some medicines require special permits from Fimea and individual reimbursement decisions or Hila listing to be reimbursable. [https://www.ema.europa.eu/en/medicines/human/EPAR/spravato|EMA Spravato EPAR] [https://finlex.fi/fi/lainsaadanto/2008/543|Finlex: Government decree on narcotics (543/2008)] [https://www.hila.fi/en/notices/reimbursable-authorized-medicinal-products-and-their-prices/|Hila: Reimbursable products and prices] [https://www.kela.fi/can-you-get-reimbursement-for-medicine-costs|Kela: Medicine reimbursement system].

Read Full Access Guide View Active Trials

Clinical Trials in Finland

Not yet recruitingPhase I

KF2024#1-trial: Esketamine Interaction Study

This open-label, Phase I trial (n=12) will investigate the effects of different methods of esketamine administration (28 mg nasal spray vs. 28 mg oral solution) with and without CYP3A4 inhibitors (grapefruit juice or cobicistat) on drug absorption and metabolism.

Started: December 9, 2024
Type: interventional
Blinding: none
Randomized: Yes
Registry ID: NCT06726382

TerminatedPhase II

A 24-Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults with Alcohol Use Disorder (AUD)

Double-blind, placebo-controlled Phase II trial (n=160) evaluating 25 mg psilocybin plus psychotherapy versus placebo in adults with Alcohol Use Disorder (AUD) over 24 weeks.

Started: June 1, 2022
Type: interventional
Blinding: double
Randomized: Yes
Registry ID: 2021-006200-33

CompletedPhase IV

A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment

Open-label single-group long-term extension (n=183) assessing long-term safety and tolerability of intranasal esketamine plus SSRI/SNRI in participants with treatment-resistant major depressive disorder who completed prior esketamine study.

Started: April 26, 2021
Type: interventional
Blinding: none
Randomized: No
Registry ID: NCT04829318

CompletedPhase III

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder (ESCAPE-TRD)

This Phase III interventional trial (n=676) evaluated flexibly dosed esketamine nasal spray versus quetiapine XR, both with a continuing SSRI/SNRI, in participants with treatment-resistant major depressive disorder.

Started: August 21, 2020
Type: interventional
Blinding: none
Randomized: Yes
Registry ID: NCT04338321

Unknown statusPhase II

Psilocybin and Depression

Randomized, double-blind, parallel Phase II trial (n=60) comparing a single oral 25 mg psilocybin dose, intranasal 125 mg ketamine, and a no-treatment group in participants with severe major depressive disorder; outcomes include depression severity and fMRI biomarkers.

Started: January 9, 2018
Type: interventional
Blinding: quadruple
Randomized: Yes
Registry ID: NCT03380442

CompletedPhase III

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression (SUSTAIN-3)

Open-label, long-term extension Phase III safety study (n≈1148) of esketamine nasal spray (flexible 28–84 mg dosing) in participants with treatment-resistant depression, induction twice weekly for 4 weeks then individualised maintenance.

Started: June 9, 2016
Type: interventional
Blinding: none
Randomized: No
Registry ID: NCT02782104

Finland

Reimbursed Care Access

Clinical Trials in Finland

KF2024#1-trial: Esketamine Interaction Study

A 24-Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults with Alcohol Use Disorder (AUD)

A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder (ESCAPE-TRD)

Psilocybin and Depression

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression (SUSTAIN-3)

Research Events

Company

Product

Legal

Finland

Reimbursed Care Access

Clinical Trials in Finland

KF2024#1-trial: Esketamine Interaction Study

A 24-Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults with Alcohol Use Disorder (AUD)

A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/​Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder (ESCAPE-TRD)

Psilocybin and Depression

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression (SUSTAIN-3)

Research Events

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder (ESCAPE-TRD)